MA30960B1 - Derives de 5-hydroxymethyl-oxazolidin-2-one - Google Patents

Derives de 5-hydroxymethyl-oxazolidin-2-one

Info

Publication number
MA30960B1
MA30960B1 MA31939A MA31939A MA30960B1 MA 30960 B1 MA30960 B1 MA 30960B1 MA 31939 A MA31939 A MA 31939A MA 31939 A MA31939 A MA 31939A MA 30960 B1 MA30960 B1 MA 30960B1
Authority
MA
Morocco
Prior art keywords
oxazolidin
hydroxymethyl
derivatives
opo3h2
nature
Prior art date
Application number
MA31939A
Other languages
English (en)
Inventor
Christian Hubschwerlen
Philippe Panchaud
Jean-Luc Specklin
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39170372&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA30960(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of MA30960B1 publication Critical patent/MA30960B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/22—Oxygen atoms attached in position 2 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'INVENTION PORTE SUR DE NOUVEAUX ANTIBIOTIQUES CHIMÉRIQUES DE FORMULE I, DANS LAQUELLE R1 REPRÉSENTE OH, OPO3H2 OU OCOR5; R2 REPRÉSENTE H, OH OU OPO3H2; A REPRÉSENTE N OU CR6; R3 REPRÉSENTE H OU FLUOR; R4 REPRÉSENTE H, ALKYLE C1-C3 OU CYCLOALKYLE; R5 EST LE RESTE D'UN ACIDE AMINÉ SE TROUVANT DANS LA NATURE, DE L'ÉNANTIOMÈRE D'UN ACIDE AMINÉ SE TROUVANT DANS LA NATURE OU DE DIMÉTHYLAMINOGLYCINE; R6 REPRÉSENTE H, ALCOXY OU HALOGÈNE; ET N EST 0 OU 1; ET SUR LES SELS (EN PARTICULIER LES SELS PHARMACEUTIQUEMENT ACCEPTABLES) DES COMPOSÉS DE FORMULE I. CES COMPOSÉS CHIMÉRIQUES SONT UTILES DANS LA FABRICATION DE MÉDICAMENTS DESTINÉS AU TRAITEMENT D'INFECTIONS (PAR EXEMPLE D'INFECTIONS BACTÉRIENNES).
MA31939A 2006-11-10 2009-06-01 Derives de 5-hydroxymethyl-oxazolidin-2-one MA30960B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IB2006054189 2006-11-10

Publications (1)

Publication Number Publication Date
MA30960B1 true MA30960B1 (fr) 2009-12-01

Family

ID=39170372

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31939A MA30960B1 (fr) 2006-11-10 2009-06-01 Derives de 5-hydroxymethyl-oxazolidin-2-one

Country Status (27)

Country Link
EP (1) EP2086968B1 (fr)
JP (2) JP4484965B2 (fr)
KR (1) KR101118402B1 (fr)
CN (1) CN101535305B (fr)
AR (1) AR063788A1 (fr)
AT (1) ATE544764T1 (fr)
AU (1) AU2007318901B2 (fr)
BR (1) BRPI0718862B8 (fr)
CA (1) CA2668280C (fr)
CL (1) CL2007003232A1 (fr)
CY (1) CY1112696T1 (fr)
DK (1) DK2086968T3 (fr)
ES (1) ES2380388T3 (fr)
HR (1) HRP20120385T1 (fr)
IL (1) IL198645A (fr)
MA (1) MA30960B1 (fr)
MX (1) MX2009004764A (fr)
MY (1) MY148847A (fr)
NO (1) NO344727B1 (fr)
NZ (1) NZ577538A (fr)
PL (1) PL2086968T3 (fr)
PT (1) PT2086968E (fr)
RU (1) RU2453546C2 (fr)
SI (1) SI2086968T1 (fr)
TW (1) TWI374138B (fr)
WO (1) WO2008056335A1 (fr)
ZA (1) ZA200904028B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003031443A1 (fr) 2001-10-04 2003-04-17 Morphochem Aktiengesellschaft für kombinatorische Chemie Antibiotiques a action duale renfermant une oxazolidinone et une quinolone ou une fraction de naphthyridinone
KR101101982B1 (ko) 2003-04-30 2012-01-02 모르포켐 악티엥게셀샤프트 퓌르 콤비나토리셰 케미 옥사졸리디논-퀴놀린 하이브리드 항생제의 탄저병 및 기타감염증의 치료용의 용도
DE10340485B4 (de) 2003-09-03 2015-05-13 Morphochem AG Aktiengesellschaft für kombinatorische Chemie Verfahren zur Herstellung von Oxazolidinon-Chinolon Hybriden
ATE401326T1 (de) † 2003-12-18 2008-08-15 Morphochem Ag Komb Chemie Oxazolidinon-chinolon hybrid antibiotika
US8158797B2 (en) 2003-12-18 2012-04-17 Morphochem Aktiengesellschaft Fur Kombinatorische Chemie Oxazolidinone-quinolone hybrid antibiotics
US8124623B2 (en) 2006-11-10 2012-02-28 Actelion Pharmaceuticals Ltd. 5-hydroxymethyl-oxazolidin-2-one-derivatives and their uses as antibacterials
PT2296651E (pt) * 2008-05-09 2012-10-01 Actelion Pharmaceuticals Ltd Derivados de 5-hidroximetil-oxazolidina-2-ona para o tratamento de doenças intestinais bacterianas
RU2616609C2 (ru) * 2011-11-08 2017-04-18 Актелион Фармасьютиклз Лтд Антибиотические производные 2-оксо-оксазолидин-3, 5-диила
MX363678B (es) 2013-05-28 2019-03-29 Morphochem Aktiengesellschaft Fuer Komb Torische Chemie Terapia de combinación que comprende oxazolidinona-quinolonas para usarse en el tratamiento de infecciones bacterianas.
HUE043786T2 (hu) 2013-05-28 2019-09-30 Morphochem Gmbh Oxazolidinon-kinolon hibrid antibakteriális hatóanyagok adagolása
WO2016079757A2 (fr) * 2014-11-19 2016-05-26 Symed Labs Limited Nouveaux procédés de préparation de 5-hydroxyméthyl-oxazolidine-2-one substitués
EP3421454B9 (fr) * 2016-02-26 2023-08-09 Otsuka Pharmaceutical Co., Ltd. Dérivé de pipéridine
US10087171B2 (en) 2016-12-19 2018-10-02 Actelion Pharmaceuticals Ltd Crystalline forms of cadazolid

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1156597A3 (ru) * 1982-04-28 1985-05-15 Е.И.Дюпон Де Немур Энд Компани (Фирма) Способ получени производных 3-( @ -алкилсульфонилфенил)оксазолидинона или их фармацевтически приемлемых кислотно-аддитивных солей
US4461773A (en) * 1982-09-15 1984-07-24 E. I. Dupont De Nemours And Company P-Oxooxazolidinylbenzene compounds as antibacterial agents
US6608081B2 (en) * 1999-08-12 2003-08-19 Ortho-Mcneil Pharmaceutical, Inc. Bicyclic heterocyclic substituted phenyl oxazolidinone antibacterials, and related compositions and methods
US6413981B1 (en) * 1999-08-12 2002-07-02 Ortho-Mcneil Pharamceutical, Inc. Bicyclic heterocyclic substituted phenyl oxazolidinone antibacterials, and related compositions and methods
ATE319710T1 (de) * 2000-12-21 2006-03-15 Pharmacia & Upjohn Co Llc Antimikrobielle chinolonderivate und ihre verwendung zur behandlung bakterieller infektionen
CA2405532A1 (fr) * 2001-02-07 2002-08-22 Ortho-Mcneil Pharmaceutical, Inc. Antibacteriens a base de pyridoarylphenyle oxazolidinone, compositions et procedes associes
WO2003031443A1 (fr) * 2001-10-04 2003-04-17 Morphochem Aktiengesellschaft für kombinatorische Chemie Antibiotiques a action duale renfermant une oxazolidinone et une quinolone ou une fraction de naphthyridinone
KR101101982B1 (ko) * 2003-04-30 2012-01-02 모르포켐 악티엥게셀샤프트 퓌르 콤비나토리셰 케미 옥사졸리디논-퀴놀린 하이브리드 항생제의 탄저병 및 기타감염증의 치료용의 용도
ZA200509147B (en) * 2003-04-30 2007-03-28 Morphochem Ag Use of oxazolidinone-quinoline hybrid antibiotics for the treatment of anthrax and other infections
KR100854211B1 (ko) * 2003-12-18 2008-08-26 동아제약주식회사 신규한 옥사졸리디논 유도체, 그의 제조방법 및 이를유효성분으로 하는 항생제용 약학 조성물
ATE401326T1 (de) * 2003-12-18 2008-08-15 Morphochem Ag Komb Chemie Oxazolidinon-chinolon hybrid antibiotika

Also Published As

Publication number Publication date
ATE544764T1 (de) 2012-02-15
MY148847A (en) 2013-06-14
EP2086968B1 (fr) 2012-02-08
CY1112696T1 (el) 2016-02-10
RU2009121812A (ru) 2010-12-20
CN101535305B (zh) 2013-09-18
IL198645A0 (en) 2010-02-17
PT2086968E (pt) 2012-04-13
PL2086968T3 (pl) 2012-07-31
BRPI0718862B1 (pt) 2020-10-13
CA2668280C (fr) 2015-02-10
AU2007318901A1 (en) 2008-05-15
JP4484965B2 (ja) 2010-06-16
NZ577538A (en) 2011-11-25
WO2008056335A1 (fr) 2008-05-15
KR101118402B1 (ko) 2012-03-07
ZA200904028B (en) 2010-08-25
CN101535305A (zh) 2009-09-16
RU2453546C2 (ru) 2012-06-20
HK1136276A1 (en) 2010-06-25
EP2086968A1 (fr) 2009-08-12
TW200829580A (en) 2008-07-16
AU2007318901B2 (en) 2013-03-14
ES2380388T3 (es) 2012-05-11
BRPI0718862A2 (pt) 2013-12-17
KR20090075875A (ko) 2009-07-09
JP2010509314A (ja) 2010-03-25
BRPI0718862B8 (pt) 2021-05-25
TWI374138B (en) 2012-10-11
AR063788A1 (es) 2009-02-18
CA2668280A1 (fr) 2008-05-15
IL198645A (en) 2014-05-28
JP5490553B2 (ja) 2014-05-14
NO344727B1 (no) 2020-03-23
DK2086968T3 (da) 2012-03-19
HRP20120385T1 (hr) 2012-06-30
NO20092209L (no) 2009-06-09
MX2009004764A (es) 2009-05-21
JP2010132677A (ja) 2010-06-17
CL2007003232A1 (es) 2008-06-27
SI2086968T1 (sl) 2012-06-29

Similar Documents

Publication Publication Date Title
MA30960B1 (fr) Derives de 5-hydroxymethyl-oxazolidin-2-one
AP1635A (en) Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease.
MA30289B1 (fr) Dérivés d'amines
TNSN07349A1 (fr) Derives de n-(n-sulfonylaminomethyl) cyclopropanecarboxamide utiles pour le traitement de la douleur
EA200870358A1 (ru) 2-(циклический амино) пиримидоновые производные в качестве ингибиторов tpk1
DE602004028150D1 (de) Aminopyrazolderivate als gsk-3-inhibitoren
MA31373B1 (fr) Composes amino-heterocycliques
MXPA03011484A (es) Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades.
MA27568A1 (fr) Derives de pyrrolopyrimidine
CY1112326T1 (el) Παραγωγα της 6-(πυριδινυλ)-4-πυριμιδονης ως αναστολεις της κινασης 1 tau πρωτεϊνης
EA200601802A1 (ru) Производные морфолина
BR0314314A (pt) Derivados do éter 4-pirrolidina-fenil-benzìlico
MA30693B1 (fr) Derives de la purine utilises en tant qu'agonistes de l'a2a
MA33618B1 (fr) Agent thérapeutique destiné aux troubles de l'humeur
ATE357453T1 (de) Comt-inhibitoren
MA31742B1 (fr) Derives de l'indol-2-one disubstitues en 3, leur preparation et leur application en therapeutique
MY158069A (en) Tricyclic compound and pharmaceutical use thereof
MA30540B1 (fr) Derives de quinolines et compositions pharmaceutiques de ces derives.
TNSN07400A1 (fr) Derives d'aminoacides
IL178167A0 (en) 1,3,4-oxadiazol-2-ones as ppar delta modulators
MA27412A1 (fr) Nouveaux pyrimidine-4,6-dicarboxamides pour l'inhibition selective de collagenases
DE602007010041D1 (de) Imidazolidinonylaminopyrimidinverbindungen zur behandlung von krebs
TN2009000205A1 (fr) Analogues de pyrazoles
DE602006009556D1 (de) Chinolin-derivate zur behandlung von mglur5-rezeptor-vermittelten erkrankungen
MA27795A1 (fr) Derives d'amine cycliques, procedes de preparation de ceux-ci et compositions pharmaceutiques les contenant